A Phase 1, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Local Muscle Injections of ACE-083 in Healthy Postmenopausal Women

Trial Profile

A Phase 1, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Local Muscle Injections of ACE-083 in Healthy Postmenopausal Women

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2018

At a glance

  • Drugs ACE 083 (Primary)
  • Indications Muscular dystrophies
  • Focus Adverse reactions; First in man
  • Sponsors Acceleron Pharma
  • Most Recent Events

    • 28 Feb 2018 Final results from this trial published online in the journal Muscle & Nerve, according to an Acceleron Pharma media release.
    • 08 Jul 2016 According to an Acceleron Pharma media release, results from this trial were presented at the 14th International Congress on Neuromuscular Disease.
    • 08 Jul 2016 Results published in the Acceleron Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top